| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S2007-Breast, Brain Mets, Sacituzumab Govitecan | 1 | Y | 1 Sacituzumab Govitecan | 44 | 28 | 4 | 3 | 3 | 0 | 0 | 06/08/2021 | 190 | 59 |
| 28 | 4 | 3 | 3 | 0 | 0 | |||||||||
| S2206-Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva | 1 | Y | 1 Tissue for MammaPrint testing | 960 | 421 | 389 | 238 | 127 | 59 | 10 | 11/27/2023 | 356 | 126 | |
| 421 | 389 | 238 | 127 | 59 | 10 | |||||||||
| 2 | Y | 2 SOC Chemotherapy | 69 | 66 | 44 | 23 | 10 | 3 | 11/27/2023 | |||||
| 3 SOC Chemotherapy + Durvalumab | 66 | 63 | 41 | 21 | 7 | 0 | ||||||||
| 135 | 129 | 85 | 44 | 17 | 3 | |||||||||
| S2212-Breast, TNBC, Neoadj Chemo + Pembro | 1 | Y | 1 Carbo + Paclitaxel + Pembro -> AC + Pembro | 2400 | 274 | 234 | 129 | 65 | 23 | 5 | 09/15/2023 | 302 | 134 | |
| 2 Carbo + Docetaxel + Pembro | 276 | 233 | 134 | 63 | 25 | 4 | ||||||||
| 550 | 467 | 263 | 128 | 48 | 9 | |||||||||
| Yes | A011801-BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib | 1 | E | Total Registrations | 54 | 13 | 7 | 4 | 1 | 1 | 03/11/2021 | 423 | 206 | |
| 54 | 13 | 7 | 4 | 1 | 1 | |||||||||
| A012103-Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab | 1 | E | Total Registrations | 20 | 15 | 9 | 6 | 3 | 0 | 08/24/2023 | 353 | 182 | ||
| 20 | 15 | 9 | 6 | 3 | 0 | |||||||||
| MA39-BREAST, Node-Pos, Reg RT vs No Reg RT | 1 | E | Total Registrations | 52 | 26 | 13 | 9 | 5 | 0 | 10/18/2019 | 381 | 150 | ||
| 52 | 26 | 13 | 9 | 5 | 0 | |||||||||
| 2 | E | Total Registrations | 49 | 24 | 11 | 7 | 4 | 1 | 10/18/2019 | |||||
| 49 | 24 | 11 | 7 | 4 | 1 | |||||||||
| NRGBR002-Brst, OMBC, II-III, SoC +/- SBRT and/or SA | 1 | T | Total Registrations | 1 | 0 | 0 | 0 | 0 | 0 | 09/22/2017 | 140 | 55 | ||
| 1 | 0 | 0 | 0 | 0 | 0 | |||||||||
| NRGBR005-Br, Stg II&IIIA, Post NAdj Chemo Br Conserv | 1 | T | Total Registrations | 7 | 0 | 0 | 0 | 0 | 0 | 06/22/2018 | ||||
| 7 | 0 | 0 | 0 | 0 | 0 | |||||||||
| No | A012301-Breast, Early Stg, Tamoxifen | 1 | E | Total Registrations | 1 | 1 | 1 | 1 | 1 | 0 | 03/07/2025 | 146 | 25 | |
| 1 | 1 | 1 | 1 | 1 | 0 | |||||||||
| EA1211-Breast, HER2+, NeoAdj Therapy | 1 | E | Total Registrations | 8 | 8 | 6 | 2 | 0 | 0 | 05/06/2024 | 128 | 58 | ||
| 8 | 8 | 6 | 2 | 0 | 0 | |||||||||
| NRGBR007-Breast, Stg I, De-Escalation of Breast RT | 1 | E | Total Registrations | 21 | 13 | 9 | 4 | 2 | 0 | 06/01/2022 | 391 | 175 | ||
| 21 | 13 | 9 | 4 | 2 | 0 | |||||||||
| 2 | E | Total Registrations | 19 | 11 | 7 | 3 | 2 | 0 | 06/01/2022 | |||||
| 19 | 11 | 7 | 3 | 2 | 0 | |||||||||
| NRGBR008-Breast, LowRisk HER2+, Radiotherapy | 1 | E | Total Registrations | 1 | 1 | 1 | 1 | 1 | 0 | 03/10/2025 | 1 | 1 | ||
| 1 | 1 | 1 | 1 | 1 | 0 | |||||||||
| NRGBR009-Breast, EarlyStg, Adjuvant Chemo | 1 | E | Total Registrations | 11 | 8 | 5 | 3 | 2 | 0 | 01/31/2024 | 434 | 186 | ||
| 11 | 8 | 5 | 3 | 2 | 0 | |||||||||
| 2 | E | Total Registrations | 11 | 8 | 5 | 3 | 2 | 0 | 01/31/2024 | |||||
| 11 | 8 | 5 | 3 | 2 | 0 | |||||||||